Publications by authors named "Ari Vanderwalde"

Claim this Profile
I
Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trial.
Richard M Zuniga, Ari VanderWalde, Lee S Schwartzberg, David R Spigel, Luke Passler

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
Michael K Wong, Mohammed M Milhem, Joseph J Sacco, Judith Michels, Gino K In, Ari M VanderWalde

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma.
Elisabetta Xue, Tolulope Adeyelu, Harris Krause, Andrew Elliott, Ranee Mehra, Ari Vanderwalde

Head Neck· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GPSai: A Clinically Validated AI Tool for Tissue of Origin Prediction during Routine Tumor Profiling.
Hassan Ghani, Anthony Helmstetter, Jennifer R Ribeiro, Todd Maney, Stephanie Rock, Ari M Vanderwalde

Cancer Res Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.
Amin H Nassar, Chul Kim, Tolulope Adeyelu, Elias Bou Farhat, Hassan Abushukair, Ari Vanderwalde

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung Adenocarcinoma.
Utsav Sen, Charles Coleman, Nishant Gandhi, Vrinda Jethalia, Deniz Demircioglu, Ari M Vanderwalde

Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
Arianna Marinello, Maria Rosa Ghigna, Julia K Rotow, Tolulope Adeyelu, Giulio Metro, Ari Vanderwalde

JAMA Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms.
Vineeth Sukrithan, Uzair Ahmed, Harris Krause, Nishant Gandhi, Andrew Elliott, Ari Vanderwalde

Endocr Relat Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Profiling of Uveal Melanoma Liver Metastases and Response to Checkpoint Inhibitors.
Yusra F Shao, Yasmine Baca, Andrew Hinton, Joanne Xiu, Ari VanderWalde

J Immunother· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and molecular correlates of acquired resistance mutations in non-small cell lung cancer (NSCLC).
Luis E Raez, Yasmine Baca, Jennifer R Ribeiro, Jorge J Nieva, Hirva Mamdani, Ari Vanderwalde

Expert Rev Anticancer Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking.
Joshua E Reuss, Jacob Zaemes, Nishant Gandhi, Phillip Walker, Sandip P Patel, Ari Vanderwalde

Lung Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer.
Alexander S Watson, Harris B Krause, Andrew Elliott, Alex Farrell, Stephen V Liu, Ari VanderWalde

Clin Lung Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: The Immune Profiles of the Molecular Subtypes of EGFR-Mutant Lung Adenocarcinomas in a Large Real-World Cohort.
J Nicholas Bodor, Joanne Xiu, Vinicius Ernani, Supreet Kaur, Hirva Mamdani, Ari VanderWalde

Clin Lung Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.
Dan Morgenstern-Kaplan, Samuel A Kareff, Asaad Trabolsi, Estelamari Rodriguez, Harris Krause, Ari M Vanderwalde

Oncologist· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies.
Elisabetta Xue, Dara Bracken-Clarke, Harris Krause, Tolulope Adeyelu, Mark G Evans, Ari M Vanderwalde

Cancers (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma.
Jordan Phillipps, George Nassief, Renee Morecroft, Tolulope Adeyelu, Andrew Elliott, Ari Vanderwalde

NPJ Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica K Lee, Ari M Vanderwalde

Cancer Discov· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Carly D Miller, John R Lozada, Nicholas A Zorko, Andrew Elliott, Allison Makovec, Ari VanderWalde

Cancer Res Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Favour A Akinjiyan, George Nassief, Jordan Phillipps, Tolulope Adeyelu, Andrew Elliott, Ari Vanderwalde

Sci Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
Gino K In, Jennifer R Ribeiro, Jun Yin, Joanne Xiu, Matias A Bustos, Ari M VanderWalde

NPJ Precis Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
Misako Nagasaka, Shannon S Zhang, Yasmine Baca, Joanne Xiu, Jorge Nieva, Ari Vanderwalde

BMC Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
Ari VanderWalde, Shay L Bellasea, Kari L Kendra, Nikhil I Khushalani, Katie M Campbell

Nat Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer.
Robert Hsu, Denaly Chen, Bing Xia, Rebecca Feldman, Wendy Cozen, Ari M Vanderwalde

Front Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peritoneal metastases from primary appendiceal and colorectal carcinomas demonstrate distinct molecular identities on comprehensive tumor analysis.
Andrew M Fleming, Benjamin W Deschner, Forrest W Williard, Justin A Drake, Ari Vanderwalde

J Surg Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
Mengni Guo, Ari M VanderWalde, Xinhua Yu, Gregory A Vidal, G Gary Tian

Clin Lung Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis